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mg/day, p < 0.0001) than patients without dyskinesias. No 
individual SNP was found to influence prevalence or time to 
onset of dyskinesias, including after adjustment for known 
risk factors. We observed that patients carrying alleles confer-
ring both high COMT activity and increased MAO-A mRNA 
expression received significantly higher maximum and mean 
daily LEDs than those with low enzyme activity/mRNA ex-
pression (max LED: 835 ± 445 vs. 508 ± 316 mg; p = 0.0056, 
mean LED: 601 ± 335 vs. 398 ± 260 mg; p = 0.025).  Conclu-
sions: Individual SNPs in BDNF, COMT and MAO-A genes did 
not influence prevalence or time to onset of dyskinesias in 
this cohort. The possibility that combined COMT and MAO-A 
genotype is a significant factor in determining an individual’s 
lifetime levodopa exposure warrants further investigation. 
 Copyright © 2013 S. Karger AG, Basel 
 Introduction 
 Levodopa-induced dyskinesias (LID) are a substantial 
barrier to effective symptomatic management of Parkin-
son’s disease (PD) and occur as a consequence of chronic 
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 Abstract 
 Background: Clinical heterogeneity in the development of 
levodopa-induced dyskinesias (LID) suggests endogenous 
factors play a significant role in determining their overall 
prevalence.  Objective: We hypothesised that single nucleo-
tide polymorphisms (SNPs) in specific genes may result in a 
clinical phenotype conducive to an increased risk of LID. 
 Methods: We examined the influence of SNPs in the catechol-
O-methyltransferase (COMT), monoamine oxidase A (MAO-A) 
and brain-derived neurotrophic factor (BDNF) genes on LID in 
a cohort of 285 pathologically confirmed Parkinson’s disease 
patients, using data from their complete disease course.  Re-
sults: Dyskinetic patients demonstrated younger age at dis-
ease onset (60.3 vs. 66.4 years, p < 0.0001), a longer disease 
duration (17.0 vs. 12.0 years, p < 0.0001) and a higher maxi-
mum daily levodopa equivalent dose (LED; 926.7 vs. 617.1 
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levodopa ( L -DOPA) treatment. Despite their high preva-
lence, therapeutic options are currently limited  [1] . Epi-
demiological evidence suggests that the onset and sever-
ity of LID varies considerably, with some patients never 
developing them despite equivalent treatment regimens. 
This observation suggests endogenous factors play a role 
in individual susceptibility to LID, and despite estab-
lished risk factors for developing LID including younger 
age at PD onset, higher  L -DOPA dose, greater disease se-
verity and longer disease duration  [2] , there has been lit-
tle research to date regarding genetic susceptibility to 
LID.
 In this study, we used a candidate gene approach to 
examine functional single nucleotide polymorphisms 
(SNPs) in which the cellular consequences of the poly-
morphism have been identified and are directly relevant 
to dyskinesias. Specifically, we focused on functional 
SNPs in genes encoding the catechol-O-methyltransfer-
ase (COMT) and monoamine oxidase A (MAO-A) en-
zymes, both of which catabolise dopamine and are cen-
tral to the therapeutic response of  L -DOPA. A valine to 
methionine substitution at codon 158 of the  COMT 
gene produces a Met variant that catabolises dopamine 
up to four times slower than its Val counterpart  [3] . Giv-
en the overlapping role of MAO with COMT, we an-
ticipated that a similar finding might be observed for the 
synonymous substitution of T to G in exon 8 of the 
 MAO-A gene, which promotes MAO-A mRNA expres-
sion  [4] .
 Finally, a valine to methionine substitution at codon 
66 of the brain-derived neurotrophic factor (BDNF) gene 
has been identified as having a putative role in influenc-
ing time to onset of dyskinesia in PD  [5] . We hypothe-
sised that these polymorphisms, individually or com-
bined, may contribute to the risk of developing dyskine-
sias in PD.
 Patients and Methods 
 Case Selection 
 We identified 285 pathologically confirmed PD cases from the 
Australian Brain Bank Network (ABBN), Australia and the Queen 
Square Brain Bank for Neurological Disorders (QSBB), UK with a 
history of  L -DOPA usage and a disease duration of at least 5 years. 
Patients were excluded if they had confirmed monogenic PD, ear-
ly symptom onset ( ≤ 40 years of age) or late symptom onset ( ≥ 80 
years of age). Approval for the collection of brain tissue as well as 
retention of and access to clinical records was granted by the Hu-
man Research Ethics Committee of the University of Melbourne 
(ABBN) and the London Multi-Centre Research Ethics Commit-
tee (QSBB).
 Genotyping 
 DNA was extracted using standard methods (QIAamp DNA Kit, 
Qiagen) and genotyping was performed via the SEQUENOM TM 
 genotyping platform at the Australian Genome Research Facility 
for  all Australian cases. Cases from the UK were genotyped for 
the  Val158Met  COMT polymorphism (dbSNP rs4680) and the 
T941G  MAO-A polymorphism (rs6323) as per Spencer et al.  [6] . 
The  BDNF  Val66Met polymorphism (rs6265) was genotyped as per 
Foltynie et al.  [7] .
 Clinical Data 
 A systematic review of patients’ medical records was performed 
by movement disorder specialists (K.B., H.L. and S.O’S.) and data 
including age at PD onset, disease duration, prevalence and time 
of onset of dyskinesia, and dopaminergic medication history were 
recorded. Levodopa equivalent dose (LED), which accounts for 
other antiparkinsonian drugs, was calculated as per Tomlinson et 
al.  [8] . An approximation of the cumulative lifetime  L -DOPA dose 
was estimated using previously published methods  [9] . Mean dai-
ly LED was obtained using the calculated lifetime estimate and 
adjusting for the number of years of  L -DOPA treatment.
 Statistical Analysis 
 We constructed Kaplan-Meier survival curves, with the time-
dependent variable set as the first recorded incidence of dyskine-
sias in dyskinetic patients, or disease duration for patients without 
dyskinesia. Time zero was set as age of PD onset, as this data was 
more reliably recorded than age at first  L -DOPA administration. 
We used Cox proportional hazards regression and generalised lin-
ear modelling to examine the relationship between genotype and 
time to onset of LID, adjusting for established risk factors. As the 
distribution of LED was skewed, we used logarithmic transforma-
tion to normalise the distribution prior to linear modelling. Statis-
tical analysis was performed using GraphPad Prism (version 5.0, 
GraphPad Software, San Diego, Calif., USA) or SPSS (version 20, 
IBM SPSS, New York, N.Y., USA).
 Results 
 Patients in our combined cohort demonstrated typical 
PD demographics, with a mean age of onset of 63.0 ± 9.2 
years, a mean disease duration of 14.8 ± 6.4 years and a 
mean maximum daily LED of 794.2 ± 431.6 mg/day. Dys-
kinesias were reported in 61.3% of patients. Dyskinetic 
patients demonstrated established risk factors for dyski-
nesias, including younger age of PD onset (60.3 vs. 66.4 
years, p < 0.0001), a longer disease duration (17.0 vs. 12.0 
years, p < 0.0001) and a higher maximum daily LED 
(926.7 vs. 617.1 mg/day, p < 0.0001) than patients without 
dyskinesias.
 When patients were stratified according to COMT, 
MAO-A or BDNF genotype, no individual genotype was 
found to independently influence the prevalence or time 
to onset of dyskinesias ( fig. 1 ). Individual genotypes were 
compared for each gene, and genotypes were pooled to 
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examine the effect of homozygosity for either allele. No 
difference was observed for any clinical feature, including 
age at onset, disease duration and maximum or mean dai-
ly LED ( table 1 ).
 We considered that individual functional SNPs may be 
unlikely to exert a significantly large effect on dyskinesia 
in isolation, and that given the overlapping function of 
COMT and MAO-A, double homozygosity for both SNPs 
may exert a greater effect than homozygosity for either 
SNP individually. However, pooling genotypes demon-
strated that patients with alleles conferring high COMT 
activity (Val/Val) and high MAO-A mRNA expression 
(T males; TT females) did not have a statistically signifi-
cantly increased prevalence of dyskinesias (58.0 vs. 43.8%, 
χ 2 = 0.62, d.f. = 1, p = 0.43) compared to those with low 
enzyme activity/mRNA expression. Interestingly, we ob-
served that patients homozygous for high COMT activity 
and high MAO-A mRNA expression alleles received sig-
Table 1.  Effect of COMT, MAO-A and BDNF genotype on incidence and time to onset of dyskinesias
COMT genotype MAO-A genotype  BDNF genotype
Met/Met Val/Met Val/Val p 
value
GG♀ + G♂ GT♀ TT♀ + T♂ p 
value
Val/ Met +
Met/Met
Val/Val p 
value
Number of cases 70 127 80 n/a 63 36 169 n/a 63+8 153 n/a
Age at PD onset, 
years 64.0±9.1 62.7±9.3 66.7±9.1 0.51 63.3±9.5 64.2±8.1 63.0±9.3 0.80 64.3±9.4 62.5±8.9 0.14
Disease duration, 
years 14.0±6.3 14.8±6.5 15.7±6.5 0.26 13.9±5.9 15.6±5.1 14.9±6.7 0.24 14.1±6.2 14.8±5.9 0.31
Time to onset of 
dyskinesia, years 8.7±4.9 7.9±4.9 8.4±4.2 0.67 8.0±4.3 9.2±5.6 8.0±4.6 0.58 8.1±4.2 7.7±3.9 0.62
Dyskinesia reported, 
% 58.5 59.6 63.9 0.78* 55.4 75.0 56.2 0.12* 62.0 62.0 >0.90*
Mean daily LED, 
mg/day 588±304 593±299 520±275 0.30 551±312 551±235 590±299 0.83 497±202 619±335 0.06
Maximum daily LED, 
mg/day 667±294 846±464 783±424 0.11 710±356 687±316 814±430 0.33 721±374 845±465 0.08
 Values are mean ± SD. Statistical analysis was non-parametric Kruskal-Wallis or Mann-Whitney test. * p value from a χ2 (Fisher’s 
exact) test. 
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 Fig. 1. Survival curves of time to onset of dyskinesia according to 
 COMT ( a ),  MAO-A ( b ) or  BDNF ( c ) genotype. Kaplan-Meier 
curves demonstrating duration from PD onset to first reported 
incidence of  LID in patients stratified according to genotype. For 
the  BDNF Val66Met polymorphism, given the low prevalence of 
the variant Met allele in European populations, Met/Met homozy-
gous patients were pooled with Val/Met heterozygotes for statisti-
cal analysis. As the  MAO-A gene is X-linked, males and females 
were analysed both separately and with male hemizygotes pooled 
with female homozygotes to directly compare the effects of T or G 
allele carriage. 
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nificantly higher maximum daily LED (835 ± 445 mg) 
than those homozygous for low activity/expression alleles 
(508 ± 316 mg; p = 0.0056), as well as a higher mean daily 
LED (601 ± 335 vs. 398 ± 260 mg; p = 0.0248). Generalised 
linear modelling confirmed the association between 
pooled COMT and MAO-A genotype and LED, with low 
activity/expression allele carriers receiving a mean maxi-
mum daily LED 43% lower (p = 0.003) than other geno-
type groups, after controlling for disease duration.
 Discussion 
 In this study of pathologically confirmed PD, poly-
morphisms in COMT, MAO-A and BDNF genes, either 
individually or combined, had no influence on the preva-
lence or time to onset of LID ( fig. 1 ). While COMT and 
BDNF have previously been implicated in the pathophys-
iology of dyskinesias, MAO-A is a novel candidate. 
COMT is primarily responsible for the breakdown of L -
DOPA when DOPA decarboxylase inhibitors are co-ad-
ministered with  L -DOPA,  blocking DOPA decarboxylase 
activity. The COMT rs4680 SNP has been associated with 
an increased risk of dyskinesias in a recent prospective 
study  [10] , although earlier cross-sectional studies failed 
to find a statistically significant effect  [11] .
 MAO-A has a similar role to COMT in catabolising 
monoamines, and the T allele of the T941G MAO-A SNP, 
which confers increased mRNA expression, has been inves-
tigated as a risk factor for developing PD  [12] . Despite this 
overlap in function, we found no evidence to suggest that 
this SNP individually influences dyskinesias. Similarly, met 
allele carriage of the BDNF Val66Met polymorphism has 
been associated with an earlier time to onset of dyskinesias 
 [5] ; however, our study found no association between 
BDNF genotype and prevalence or time to onset of dyski-
nesias, which may be a reflection of different study designs.
 Our data suggest a putative relationship between com-
bined COMT and MAO-A genotype and total lifetime  L -
DOPA exposure. Patients with alleles conferring high 
COMT activity and high MAO-A mRNA expression re-
ceived significantly higher  L -DOPA exposure than low 
activity/expression carriers. Although these data should 
be interpreted with caution given the small sample size of 
this subgroup of double homozygotes, we note that if we 
reduce our p value to p < 0.01 to correct for multiple com-
parisons, our data remain statistically significant.
 In a clinical setting, patients with increased COMT 
enzyme activity and increased MAO-A expression will 
metabolise  L -DOPA faster, which may result in increased 
wearing off, necessitating higher or more frequent  L - 
DOPA doses over the day, resulting in the higher lifetime 
exposure to  L -DOPA observed in our study. This finding 
warrants replication in a larger cohort, although it is dif-
ficult to increase the sample size of a post-mortem cohort 
without adding cases from additional tissue banks, intro-
ducing genetic diversity that can obscure results.
 The present study has some important limitations. 
The data were collected retrospectively using clinical case 
notes with the implicit assumption that a reasonably con-
sistent threshold would apply for specialists to report dys-
kinesias. While our patient demographics appear to rep-
resent a typical PD population on the basis of age of onset 
and disease duration, there is likely to be a selection bias 
in cases submitted for brain banking.
 In summary, we find no evidence to suggest the SNPs 
in COMT, MAO-A or BDNF examined in this study influ-
ence the prevalence or time to onset of LID. Our data sug-
gest that combined COMT and MAO-A genotype may 
influence  L -DOPA use, but further studies in different 
populations are required to clarify this effect.
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